Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

806658

registered interest
date	14/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps Public Health England is taking to measure the uptake of Green Book recommended immunisations among adult patients in clinical risk groups.
tabling member constituency	Alyn and Deeside
tabling member printed	Mark Tami
uin	119734
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>Data on patients within clinical ‘at risk’ groups are held on general practice (GP) systems, within the personal patient records. The same systems are used to record vaccinations when given. Public Health England uses GP data to monitor uptake for vaccines recommended for adults in accordance with the Green Book. These include periodic analyses of uptake among at risk groups.</p><p> </p><p>Uptake reports are published weekly, monthly, quarterly or annually depending on the programme and can be found on:</p><p><a href="https://www.gov.uk/government/collections/vaccine-uptake" target="_blank">https://www.gov.uk/government/collections/vaccine-uptake</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 21/12/2017 17:05:23 answering member 4067 label Biography information for Steve Brine
tabling member	1383 label Biography information for Mark Tami

806108

registered interest
date	13/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he plans to publish the Cost Effectiveness Methodology for Immunisation Programmes and Procurement report into vaccine cost-effectiveness.
tabling member constituency	Faversham and Mid Kent
tabling member printed	Helen Whately
uin	119309
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>The Cost Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP) report is technically complex with potential implications that could extend beyond immunisation. This report was referred to the Appraisal Alignment Working Group (AAWG) for further advice. The Department will consider the CEMIPP report alongside the AAWG advice and remains committed to publishing the CEMIPP report in due course.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 21/12/2017 16:44:23 answering member 4067 label Biography information for Steve Brine
tabling member	4527 label Biography information for Helen Whately

782015

registered interest
date	01/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the answer by Lord O'Shaughnessy on 30 October (HL Deb, col 1152), whether they will publish the tariff of fees paid to pharmacists for providing vaccinations in retail and community settings.
tabling member printed	Lord Hughes of Woodside
uin	HL2796
answer	answer is ministerial correction date of answer 14/11/2017 answer text <p>Community pharmacy contractors are paid £9.14 per vaccination to immunise patients against seasonal flu. General practitioner contractors are paid £9.80 per vaccination to immunise patients against seasonal flu. Both are reimbursed for the cost of the vaccine administered.</p><p> </p><p>The differential is because GPs are required to call and recall eligible patients from their practice list for the vaccination. Community pharmacy cannot do this as they do not have a practice list.</p><p> </p><p>Information on the payment arrangements for community pharmacy delivered flu vaccination for 2017/18 is contained in the <em>Service Specification, Community pharmacy seasonal influenza advanced service</em>. This was published by NHS England in August 2017. A copy is attached.</p> answering member printed Lord O'Shaughnessy question first answered 14/11/2017 17:14:12 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name 17-18-service-specification-seasonal-flu.pdf title Service specification
tabling member	1051 label Biography information for Lord Hughes of Woodside

771264

registered interest
date	16/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how the risks and benefits of new vaccinations are assessed; and who is responsible for that assessment.
tabling member printed	The Countess of Mar
uin	HL2065
answer	answer is ministerial correction date of answer 25/10/2017 answer text <p>All new vaccines that are to be marketed in the United Kingdom require a Marketing Authorisation issued either by the Medicines and Healthcare products Regulatory Agency (MHRA), the UK national competent authority, or by the European Commission.</p><p> </p><p>Applications for Marketing Authorisations for any new medicine, including vaccines, must contain data on the quality, safety and efficacy of the medicinal product. In the case of vaccines, information on the safety and immunogenicity of the antigenic components of the candidate vaccine in the target population must be provided. These data are assessed by MHRA and, where applicable, the European Medicines Agency. This information is fully evaluated to establish the efficacy and safety of the medicinal product, and to ensure that the balance of the expected benefits and potential risks is favourable. Safety evaluation of vaccines continues in the post-licensing period and throughout the life-cycle of the product.</p><p> </p><p>An independent external review of the authorisation of new medicines, including vaccines, is provided by the Commission on Human Medicines and its Expert Advisory Groups, which advises the MHRA and Ministers on the safety, efficacy and quality of medicinal products. The members of the Commission are appointed by Ministers.</p><p> </p><p>The Joint Committee on Vaccination and Immunisation (JCVI), another independent expert advisory committee and statutory body, advises the Government on matters relating to vaccination and immunisation. The JCVI advises the Government on all changes to the national vaccination programme, including on the introduction of new vaccines. The JCVI reviews evidence on the potential health benefits and the safety of vaccines when developing its advice. The JCVI keeps all UK vaccination programmes under review, including regular updates from the MHRA on vaccine associated adverse events reported in the UK.</p> answering member printed Lord O'Shaughnessy question first answered 25/10/2017 15:01:07 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

771526

registered interest
date	16/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, for what reasons the Cost-Effectiveness Methodology for Immunisation Programmes and Procurements working group's report into vaccine cost effectiveness has not been published.
tabling member constituency	Bristol East
tabling member printed	Kerry McCarthy
uin	108067
answer	answer is ministerial correction date of answer 24/10/2017 answer text <p>The Cost Effectiveness Methodology for Immunisation Policy and Procurement (CEMIPP) report is technically complex with potential implications that could extend beyond immunisation. This report has been referred to the Appraisal Alignment Working Group (AAWG) for its analytical view.</p><p> </p><p>It is important not to pre-empt AAWG’s considerations but to give them the time they need to consider the CEMIPP report, reflect on subsequent research, and to report back to ministers on the analytical elements of the report.</p><p> </p><p>The AAWG is due to report back to ministers later in the year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/10/2017 10:53:14 answering member 4067 label Biography information for Steve Brine
tabling member	1491 label Biography information for Kerry McCarthy

755811

registered interest
date	04/09/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the rate of complete immunisation is for children under the age of four.
tabling member constituency	Birkenhead
tabling member printed	Frank Field
uin	7130
answer	answer is ministerial correction date of answer 11/09/2017 answer text <p>Public Health England reports information on the rate of complete immunisation for children at 12 months, 24 months and at five years. The most recently published report is the Quarterly vaccination coverage statistics for children aged up to five years in the United Kingdom (COVER programme): January to March 2017 which can be accessed here:</p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/623860/hpr2317_COVER.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/623860/hpr2317_COVER.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2017 15:52:10 answering member 4067 label Biography information for Steve Brine
tabling member	478 label Biography information for Lord Field of Birkenhead

631875

registered interest
date	08/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether it is planned that the review by the Cost Effectiveness Methodology for Immunisation Policy and Procurement working group into the cost effectiveness framework by which vaccines are assessed will consider peace of mind analysis.
tabling member constituency	South Down
tabling member printed	Ms Margaret Ritchie
uin	52358
answer	answer is ministerial correction date of answer 14/11/2016 answer text <p>The Cost Effectiveness Methodology for Immunisation Programmes and Procurements (CEMIPP) working group has finished its work.</p><p> </p><p>The timetable for publishing its report has not yet been confirmed.</p><p> </p><p>As stated by Professor John Cairns, Chair of the CEMIPP working group, during the Petitions Committee evidence session on 22 March 2016, ‘peace of mind’ was part of the working group’s discussions.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 52359 question first answered 14/11/2016 15:13:02 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

631876

registered interest
date	08/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the expected publication date is for the report by Cost Effectiveness Methodology for Immunisation Policy and Procurement Working Group on the cost effectiveness framework by which vaccines are assessed.
tabling member constituency	South Down
tabling member printed	Ms Margaret Ritchie
uin	52359
answer	answer is ministerial correction date of answer 14/11/2016 answer text <p>The Cost Effectiveness Methodology for Immunisation Programmes and Procurements (CEMIPP) working group has finished its work.</p><p> </p><p>The timetable for publishing its report has not yet been confirmed.</p><p> </p><p>As stated by Professor John Cairns, Chair of the CEMIPP working group, during the Petitions Committee evidence session on 22 March 2016, ‘peace of mind’ was part of the working group’s discussions.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 52358 question first answered 14/11/2016 15:13:02 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

628271

registered interest
date	03/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they intend to publish the report commissioned by the Department of Health on the Cost Effectiveness Methodology for Immunisation Programmes and Procurement, and if so, when.
tabling member printed	Baroness Walmsley
uin	HL3006
answer	answer is ministerial correction date of answer 16/11/2016 answer text <p>The Department will be publishing the Cost Effectiveness Methodology for Immunisation Programmes and Procurements report in due course. The timetable has not yet been confirmed.</p><p> </p><p>A decision on consultation has not yet been made.</p> answering member printed Lord Prior of Brampton grouped question UIN HL3007 question first answered 16/11/2016 15:29:07 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2547 label Biography information for Baroness Walmsley

628272

registered interest
date	03/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether there will be a consultation on changes to the methodology used by the Joint Committee on Vaccination and Immunisation that result either from the report commissioned by the Department of Health on the Cost-Effectiveness Methodology for Immunisation Programmes and Procurement or from the work of the Department of Health’s Appraisal Alignment Working Group.
tabling member printed	Baroness Walmsley
uin	HL3007
answer	answer is ministerial correction date of answer 16/11/2016 answer text <p>The Department will be publishing the Cost Effectiveness Methodology for Immunisation Programmes and Procurements report in due course. The timetable has not yet been confirmed.</p><p> </p><p>A decision on consultation has not yet been made.</p> answering member printed Lord Prior of Brampton grouped question UIN HL3006 question first answered 16/11/2016 15:29:07 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2547 label Biography information for Baroness Walmsley